An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy in Women with Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer

Study Status

Open to Enrollment

Study Description

This is a clinical trial for women with advanced or metastatic HER2-positive or triple negative breast cancer who have not received prior systemic treatment for the metastatic cancer. The purpose of the study is to determine if the experimental drug ganetespib is a safe and effective treatment for advanced breast cancer.

Ganetespib inhibits Hsp90, a protein that is essential to the function of other proteins that drive the growth of many cancers. In earlier research ganetespib has been shown to have anti-tumor activity. Ganetespib may therefore slow or stop cancer from growing.

Study participants will be enrolled into one of two cohorts:

  • Cohort A: HER2+ breast cancer
  • Cohort B: triple negative breast cancer

Ganetespib monotherapy will be administered via infusion twice weekly for 3 consecutive weeks followed by one week rest of a 4 week cycle. Participants will initially receive 3 cycles of ganetespib for a total of 12 weeks. Study participants who respond to treatment may continue to receive ganetespib therapy beyond the initial 12 weeks.

Follow the Weill Cornell Breast Center Online:

Blog: CornellBreastCenter.com

Facebook: http://www.facebook.com/CornellBreastCenter

Twitter: https://twitter.com/cornellbreastcr 

Disease Status and/or Stage

Previously Untreated Metastatic HER2-Positive or Triple Negative Breast Cancer

Sponsor

Synta

Key Eligibility

  • Women age 18 and older
  • Advanced or metastatic breast cancer
  • No prior systemic therapy for metastatic breast cancer
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Linda Vahdat, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Erica Bersin
Tel: (646) 962-8232
[email protected]

Top of page